General Information of Drug (ID: DMGXS8L)

Drug Name
CD20Bi aATC Drug Info
Synonyms
CD20Bi activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; CD20Bi-armed ATC (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma); Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute
Indication
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMGXS8L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [2]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [3]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [4]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [5]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [6]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [7]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [8]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [9]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [10]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [12]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [3]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [4]
Ibritumomab DMG594T Non-hodgkin lymphoma 2B33.5 Approved [13]
Rituximab DM1YVZT Central nervous system non-hodgkin lymphoma Approved [14]
Ublituximab DMHTY9W Multiple sclerosis 8A40 Approved [15]
Tositumomab DMMYZ3D Non-hodgkin lymphoma 2B33.5 Approved [13]
Obinutuzumab DM3BVAE Chronic lymphocytic leukaemia 2A82.0 Approved [16]
Ofatumumab DM295PR Chronic lymphocytic leukaemia 2A82.0 Approved [17]
Rituximab DM1YVZT Central nervous system non-hodgkin lymphoma Approved [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Modulator [1]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Modulator [1]

References

1 CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
4 Clinical pipeline report, company report or official report of Genmab.
5 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
7 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
8 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
9 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
10 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
11 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
14 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
15 The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
17 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
18 Clinical pipeline report, company report or official report of Genentech (2009).